Druggio Logo

Druggio

Renal anemia

Renal anemia is one of the most frequent complications of chronic kidney disease. Anemia leads to a decrease in oxygen delivery to vital organs, which is initially compensated for by tachycardia and cardiac hypertrophy, but eventually leads to the development of cardiovascular disease. Renal anemia is caused by the deficiency of endogenous erythropoietin (EPO) due to renal dysfunction. EPO is a glycoprotein hormone that has the role of the primary regulator of erythropoiesis. Formerly, treatment options were essentially limited to blood transfusions and androgen therapy, with its risks. However, since the late 1980s, the availability of recombinant human erythropoietin has revolutionized the management of renal anemia, and erythropoiesis-stimulating agents (ESAs) are now the mostly widely used drugs.

Drugs that treat Renal anemia

Musredo

Made by

Bayer

Approval date

2021/1/22

Treats

Enaroy

Approval date

2020/9/25

Treats

Duvroq

Approval date

2020/6/29

Treats

Vafseo

Approval date

2020/6/29

Treats

Evrenzo

Approval date

2019/9/20

Treats

Mircera

Approval date

2011/4/22

Treats

Nesp

Made by

Kyowa Kirin

Approval date

2007/4/18